Retrospective Study
Copyright ©The Author(s) 2017.
World J Hepatol. Aug 8, 2017; 9(22): 959-966
Published online Aug 8, 2017. doi: 10.4254/wjh.v9.i22.959
Table 2 Comparison between patients with severe hypoxic hepatitis who died and survived n (%)
Died (n = 53)Survived (n = 22)P value
Demographics
Age64.3 ± 17.656.3 ± 12.80.059
Male gender35 (66.0)8 (36.4)0.018
Race (Chinese/Malay/Indian)36/13/415/7/00.373
Pre-existing co-morbidities
Pre-existing ischemic heart disease27 (50.9)12 (54.5)0.793
Pre-existing cardiac failure16 (30.2)11 (50.0)0.104
Pre-existing renal failure19 (35.8)8 (36.4)0.966
Precipitating conditions
Documented hypotension45 (84.9)14 (63.6)0.041
Documented bradycardia9 (17.0)2 (9.1)0.379
Documented metabolic acidosis33 (62.3)10 (45.5)0.180
Baseline laboratory parameters1
Albumin (g/L)23.7 ± 6.829.1 ± 5.80.001
Bilirubin (μmol/L)79.2 ± 84.468.8 ± 79.70.625
ALT (U/L)2051 ± 16012880 ± 16740.048
AST (U/L)5093 ± 29434440 ± 31030.395
ALT/AST ratio_D120.50 ± 0.801.18 ± 2.150.051
GGT (U/L)111 ± 67158 ± 1230.161
Creatine kinase2949 ± 6180395 ± 4190.006
Creatine kinase MB37.1 ± 56.613.5 ± 20.70.015
Troponin T (Trop T)2.02 ± 4.210.49 ± 1.420.031
Lactate dehydrogenase2503 ± 25524035 ± 36710.229
Creatinine (mmol/L)297.3 ± 172.9376.6 ± 276.30.143
Prothombin time (seconds)27.8 ± 12.527.7 ± 11.90.980
Peak ALT (U/L)2572 ± 20263464 ± 15750.069
Peak AST (U/L)6223 ± 31385131 ± 31100.176